SINOPEC CORP (00386) reported a net profit attributable to shareholders of RMB38.988 billion for the first three quarters, up 30% year on year.
Sinopec Corp (00386) announced its results for the first three quarters of 2026. Under Chinese Accounting Standards for Business Enterprises, operating revenue was approximately RMB2.206296 trillion, up 4.4% year on year; net profit attributable to shareholders of the listed company was RMB38.988 billion, up 30% year on year; basic earnings per share were RMB0.323.
SINOPEC CORP (00386) announced its results for the first three quarters of 2026. Under the Accounting Standards for Business Enterprises of China, operating revenue was approximately RMB2.206296 trillion, up 4.4% year on year; net profit attributable to shareholders of the listed company was RMB38.988 billion, up 30% year on year; basic earnings per share were RMB0.323.
Under International Financial Reporting Standards, profit attributable to shareholders of the company for the first three quarters was RMB40.167 billion, up 25.3% year on year, of which the third quarter was RMB13.600 billion, up 63.6% year on year.
The announcement said the profit growth was mainly due to improved price spreads for refining and chemical products, the company's efforts to increase production of high value-added products such as aviation kerosene and refining by-products, and inventory gains brought by rising crude oil prices.
Related Articles

SINOHYTEC (02402) reported a net loss attributable to shareholders of approximately RMB187 million for the first three quarters, narrowing by about 40% year-on-year.

Merck & Co., Inc. (MRK.US) Q3 results beat expectations: Keytruda and Gardasil perform well, full-year guidance raised.

MICROTECH MED-B (02235) repurchased 1,800 shares on October 29 for approximately HK$12,100.
SINOHYTEC (02402) reported a net loss attributable to shareholders of approximately RMB187 million for the first three quarters, narrowing by about 40% year-on-year.

Merck & Co., Inc. (MRK.US) Q3 results beat expectations: Keytruda and Gardasil perform well, full-year guidance raised.

MICROTECH MED-B (02235) repurchased 1,800 shares on October 29 for approximately HK$12,100.






